Mineralys Therapeutics, Inc. Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension
December 22, 2023 at 02:05 pm
Share
Mineralys Therapeutics, Inc. announced that the first subject has been dosed in the Launch-HTN (NCT06153693) pivotal trial to evaluate the safety and efficacy of lorundrostat for the treatment of uncontrolled hypertension or resistant hypertension, when used as an add-on therapy to prescribed background treatment. Launch-HTN is the second of two clinical trials under the planned pivotal program to evaluate the safety and efficacyof lorundrostat when added to subjects' existing background hypertension treatment. This trial is designed to model real world treatment of uncontrolled hypertension and resistant hypertension in the primary care setting.
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone. The Companyâs product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that the Company is initially developing for the treatment of patients with uncontrolled hypertension (uHTN). Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. The Company completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uHTN. In addition to hypertension, the Company intends to develop lorundrostat for the treatment of chronic kidney disease (CKD).
MINERALYS THERAPEUTICS, INC. 
